BioMarin Pharmaceutical Inc. (NASDAQ:BMRN - Get Free Report) EVP Gregory Friberg sold 5,147 shares of the firm's stock in a transaction that occurred on Wednesday, November 18th. The stock was sold at an average price of $58.81, for a total transaction of $302,695.07. Following the sale, the executive vice president owned 42,585 shares of the company's stock, valued at approximately $2,504,423.85. The trade was a 10.78% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.
BioMarin Pharmaceutical Price Performance
BMRN traded down $0.01 during trading on Thursday, reaching $61.42. 5,206,755 shares of the company were exchanged, compared to its average volume of 2,142,394. The company's 50-day moving average is $58.50 and its two-hundred day moving average is $58.52. The company has a market cap of $11.90 billion, a price-to-earnings ratio of -614.20, a P/E/G ratio of 0.78 and a beta of 0.21. BioMarin Pharmaceutical Inc. has a 12-month low of $49.26 and a 12-month high of $70.98. The company has a quick ratio of 1.32, a current ratio of 2.44 and a debt-to-equity ratio of 0.56.
BioMarin Pharmaceutical (NASDAQ:BMRN - Get Free Report) last released its earnings results on Monday, November 2nd. The biotechnology company reported $0.23 EPS for the quarter, beating analysts' consensus estimates of ($0.05) by $0.28. BioMarin Pharmaceutical had a positive return on equity of 5.58% and a negative net margin of 0.52%. The business had revenue of $1.02 billion for the quarter, compared to analysts' expectations of $1.02 billion. During the same quarter in the prior year, the firm earned $0.12 earnings per share. The firm's revenue was up 32.0% on a year-over-year basis. Research analysts forecast that BioMarin Pharmaceutical Inc. will post 2.20 earnings per share for the current fiscal year.
Institutional Investors Weigh In On BioMarin Pharmaceutical
Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Kestra Advisory Services LLC increased its position in BioMarin Pharmaceutical by 23.4% during the third quarter. Kestra Advisory Services LLC now owns 4,520 shares of the biotechnology company's stock worth $271,000 after purchasing an additional 857 shares during the last quarter. Coastal Bridge Advisors LLC purchased a new stake in shares of BioMarin Pharmaceutical during the third quarter worth approximately $312,000. Snow Capital Management LLC purchased a new stake in shares of BioMarin Pharmaceutical in the third quarter valued at approximately $1,260,000. Allworth Financial LP grew its holdings in BioMarin Pharmaceutical by 12.6% in the third quarter. Allworth Financial LP now owns 6,717 shares of the biotechnology company's stock valued at $403,000 after purchasing an additional 754 shares during the last quarter. Finally, Strategic Global Advisors LLC acquired a new stake in shares of BioMarin Pharmaceutical during the third quarter valued at $1,734,000. Hedge funds and other institutional investors own 98.71% of the company's stock.
Analysts Set New Price Targets
BMRN has been the topic of a number of recent analyst reports. Jefferies Financial Group increased their price objective on shares of BioMarin Pharmaceutical from $104.00 to $105.00 and gave the stock a "buy" rating in a research report on Monday, August 31st. Wall Street Zen raised BioMarin Pharmaceutical from a "hold" rating to a "buy" rating in a report on Sunday, November 8th. Piper Sandler increased their price target on BioMarin Pharmaceutical from $88.00 to $90.00 and gave the company an "overweight" rating in a report on Tuesday, September 1st. Canaccord Genuity Group increased their target price on shares of BioMarin Pharmaceutical from $111.00 to $114.00 and gave the stock a "buy" rating in a report on Monday, August 10th. Finally, William Blair upgraded shares of BioMarin Pharmaceutical to a "hold" rating in a report on Wednesday, September 23rd. Three investment analysts have rated the stock with a Strong Buy rating, fifteen have given a Buy rating, six have given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $87.22.
View Our Latest Research Report on BioMarin Pharmaceutical
About BioMarin Pharmaceutical
(
Get Free Report)
BioMarin Pharmaceutical is a biotechnology company focused on developing and commercializing medicines for people with rare genetic diseases. Its work includes research, clinical development, manufacturing and distribution of therapies for conditions that often have limited treatment options. The company's marketed treatments address disorders including phenylketonuria, mucopolysaccharidosis, late-infantile neuronal ceroid lipofuscinosis, achondroplasia and hemophilia A. Its products include Kuvan and Palynziq for phenylketonuria, Vimizim for Morquio A syndrome, Brineura for CLN2 disease, Voxzogo for achondroplasia and Roctavian for hemophilia A. Founded in 1997 and headquartered in San Rafael, California, BioMarin serves patients and healthcare providers in the United States and international markets, including Europe.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider BioMarin Pharmaceutical, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and BioMarin Pharmaceutical wasn't on the list.
While BioMarin Pharmaceutical currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.